Regorafenib in metastatic colorectal cancer.
Mayo Clinic, Rochester, Minnesota.
Axel
A
Grothey
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D009362:Neoplasm Metastasis; D010166:Palliative Care; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012106:Research / Q000639:trends; D012107:Research Design; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib